地龙降压胶囊联合西医常规治疗肝阳上亢型原发性高血压伴亚临床动脉硬化临床研究  

Clinical Study on Dilong Jiangya Capsule in Treatment of Essential Hypertension with Subclinical Atherosclerosis of Hyperactivity of Liver Yang Type

作　　者：刘萍萍 贾龙[2] 李应东[2] 刘斌[2] 赵信科 LIU Ping-ping;JIA Long;LI Ying-dong;LIU Bin;ZHAO Xin-ke(Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou 730000, China;Gansu University of Chinese Medicine, Lanzhou 730000, China)

机构地区：[1]甘肃中医药大学附属医院,甘肃兰州730000 [2]甘肃中医药大学,甘肃兰州730000

出　　处：《中国中医药信息杂志》2018年第4期24-27,共4页Chinese Journal of Information on Traditional Chinese Medicine

基　　金：国家自然科学基金地区基金(81760798)

摘　　要：目的探讨地龙降压胶囊联合常规西药治疗对肝阳上亢型原发性高血压伴亚临床动脉硬化患者的降压作用及对动脉硬化的改善情况。方法采用随机数字表法将120例肝阳上亢型原发性高血压伴亚临床动脉硬化患者分为治疗组和对照组各60例。对照组遵循个体化、小剂量、长效、联合的原则予常规降压治疗。治疗组在对照组基础上予地龙降压胶囊,每次1粒,每日2次,晨起及睡前口服。均连续治疗6周。观察2组治疗前及治疗2、4、6周血压、颈动脉内膜中层厚度(IMT)、脉搏波传导速度(PWV)和踝臂指数(ABI),评价临床疗效。结果治疗组、对照组分别脱落2、3例。治疗组总有效率为91.38%(53/58),对照组为82.46%(47/57),治疗组明显优于对照组,差异有统计学意义(P<0.05)。与本组治疗前比较,2组治疗后血压水平明显降低(P<0.05);治疗组治疗后明显低于对照组(P<0.05)。与本组治疗前比较,治疗2、4周2组IMT、PWV明显下降,治疗2、4、6周ABI明显下降,差异有统计学意义(P<0.05)。2组治疗4周IMT、PWV比较差异有统计学意义(P<0.05);2组治疗2、4周ABI比较差异有统计学意义(P<0.05);2组治疗6周IMT、PWV、ABI比较差异有统计学意义(P<0.05)。结论地龙降压胶囊联合常规西药治疗原发性高血压伴亚临床动脉硬化可增强降压效果,在一定程度上改善IMT、PWV、ABI。Objective To investigate the synergistic antihypertensive effect of Dilong Jiangya Capsules on patients with essential hypertension with subclinical atherosclerosis of liver yang hyperactivity type and its effect on arteriosclerosis.Methods Totally120patients with essential hypertension with subclinical atherosclerosis were randomly divided into treatment group(60cases)and control group(60cases).Control group received antihypertensive treatment by following the individual,low-dose,long-term,combined principle,while treatment group was given Dilong Jiangya Capsules on the basis of control group,one capsule per time,twice a day,orallytaken during early morning and bedtime.The treatment for both groups lasted for six weeks.Blood pressure,carotid artery intima-media thickness(IMT),pulse wave velocity(PWV)and ankle-brachial index(ABI)were observed before and2,4and6weeks after treatment.Blood pressure clinical efficacy was evaluated.Results Two and three cases were lost in the treatment group and control group,respectively.The total effective rate was91.38%(53/58)in the treatment group and82.46%(47/57)in the control group,and the treatment group was significantly better than the control group(P<0.05).Compared with before treatment,the blood pressure of the two groups was significantly lower(P<0.05),and the treatment group was significantly lower than the control group(P<0.05).Compared with before treatment,the levels of IMT and PWV in both groups significantly decreased at2and4weeks of treatment,and ABI at2,4and6weeks of treatment decreased significantly(P<0.05).There was statistical difference in IMT and PWV between the two groups at4weeks of treatment(P<0.05).There was statistical difference in ABI between the two groups at2and4weeks of treatment(P<0.05).There was statistical difference in IMT,PWV and ABI between the two groups at6weeks of treatment(P<0.05).Conclusion Dilong Jiangya Capsules combined with conventional antihypertensive treatment of essential hypertension with subclinical atherosclerosis can enhance th

关 键 词：原发性高血压 地龙降压胶囊 颈动脉内膜中层厚度 脉搏波传导速度 踝臂指数 

分 类 号：R259.441[医药卫生—中西医结合]